Hello There

Here are four benefits that virtual meetings have over in-person conferences.

As the Covid-19-induced new norm is underway, communication is rapidly and universally approaching to an online format. Fortunately, the virtual space provides the necessary capabilities for continued, effective, and personal collaboration. Bioinsider is engaged in providing the scientific community a virtual experience proportionate to in-person meetings, roundtables, and conferences.

The number of participants is s

As Joe Biden is now officially the President of the United States, healthcare is one of the top priorities the new administration will change. The major focus will be to create a public healthcare system similar yet better to the Affordable Care Act (ACA). Below, we’ll discuss some of the specific ways that Joe Biden’s new healthcare policy may affect investors’ decisions for 2021.

Managed care companies are health organizations that contract with insurers or self-insured employers to finance a

2020 will soon be a record year for biotechnology. In the first half of 2020, the biotechnology industry obtained $16.55 billion in investment. Cell and gene therapy biotechs secured the lion share of investment by raising $10.7 billion. Notably, the amount raised by cell and gene therapy biotechs increased by 120% during the same time period of 2019.1 Thus far, the increase in this year’s investing appears to be driven by venture capitalists (VCs) as they contributed approximately 30% of the to

Academic and Industry collaborations are not a new concept that was created in the 21st century. The concept dates back to the 1970s, and “since 1973, the National Science Foundation’s (NSF) Industry-University Cooperative Research Centers Program (IUCRC) has facilitated partnerships between scientific researchers from both industry and academia to drive innovation.” 1 Below, Bioinsider will describe the power of academia-industry collaborations.

One of the most significant benefits of academic

In regards to capturing venture capital investment, 2020 has been a phenomenal year for biotechnology startups, only if you were the right kind. Startups that had previously received investments prior to the COVID-19 pandemic obtained the most investment. In contrast, startups that launched without prior investment were largely ignored by venture capitalists. Here, we briefly describe on why in 2020 venture capitalists emphasized investments on versatile startups, which have put emerging and imp

Although CRISPR has become increasingly synonymous with a disease-free future, there are issues pertaining to the control of the technology that could impact its future influence in the world of science.

CRISPR/Cas-9 has had many clinical successes that have proven the technology’s worth in the world. CRISPR’s current clinical successes have been in hemoglobinopathies, including β-thalassemia and sickle cell disease (SCD). For example, CTX001 is a Cas9 gene-edited hematopoietic stem cell therap